BACKGROUND: Recent studies have assessed the relationship between hypoxia-inducible factor 1α (HIF-1α) expression and prognosis in breast cancer patients with inconsistent conclusions. To comprehensively and quantitatively summarize the evidence on the survival of patients with breast cancer, a meta-analysis was performed. METHODS: Systematic literature searching was applied to the databases of PubMed, Embase and Web of science until April 1, 2013. Pooled HR with 95% CI was used to evaluate the association between HIF-1α expression and survival in breast cancer patients. RESULTS: Fourteen papers including 2933 patients were subjected to the final analysis. Of these, 7 provided data on overall survival (OS), 8 on disease-free survival (DFS), 3 on distant metastasis-free survival (DMFS) and 3 on relapse-free survival (RFS). We observed that high expression of HIF-1α in breast cancer patients was an indicator of poor prognosis on OS (HR = 1.46, 95% CI: 1.12-1.92, P = 0.006), DFS (HR = 1.91, 95% CI: 1.43-2.57, P<0.001), DMFS (HR=2.17 95% CI: 1.16-4.05, P=0.015) and RFS (HR=1.33 95% CI: 1.09-1.61, P=0.005). Significant heterogeneity was observed in the analyses of OS and DFS. Subgroup analyses by the cut-off value and antibody for IHC were conducted. CONCLUSION: High expression of HIF-1α indicated a poor prognosis for patients with breast cancer.
BACKGROUND: Recent studies have assessed the relationship between hypoxia-inducible factor 1α (HIF-1α) expression and prognosis in breast cancerpatients with inconsistent conclusions. To comprehensively and quantitatively summarize the evidence on the survival of patients with breast cancer, a meta-analysis was performed. METHODS: Systematic literature searching was applied to the databases of PubMed, Embase and Web of science until April 1, 2013. Pooled HR with 95% CI was used to evaluate the association between HIF-1α expression and survival in breast cancerpatients. RESULTS: Fourteen papers including 2933 patients were subjected to the final analysis. Of these, 7 provided data on overall survival (OS), 8 on disease-free survival (DFS), 3 on distant metastasis-free survival (DMFS) and 3 on relapse-free survival (RFS). We observed that high expression of HIF-1α in breast cancerpatients was an indicator of poor prognosis on OS (HR = 1.46, 95% CI: 1.12-1.92, P = 0.006), DFS (HR = 1.91, 95% CI: 1.43-2.57, P<0.001), DMFS (HR=2.17 95% CI: 1.16-4.05, P=0.015) and RFS (HR=1.33 95% CI: 1.09-1.61, P=0.005). Significant heterogeneity was observed in the analyses of OS and DFS. Subgroup analyses by the cut-off value and antibody for IHC were conducted. CONCLUSION: High expression of HIF-1α indicated a poor prognosis for patients with breast cancer.
Authors: Alexandra Giatromanolaki; Anastasia G Gkegka; Stamatia Pouliliou; Eirini Biziota; Stylianos Kakolyris; Michael Koukourakis Journal: Breast Cancer Res Treat Date: 2022-04-28 Impact factor: 4.872
Authors: Joshua C Black; Elnaz Atabakhsh; Jaegil Kim; Kelly M Biette; Capucine Van Rechem; Brendon Ladd; Paul D Burrowes; Carlos Donado; Hamid Mattoo; Benjamin P Kleinstiver; Bing Song; Grasiella Andriani; J Keith Joung; Othon Iliopoulos; Cristina Montagna; Shiv Pillai; Gad Getz; Johnathan R Whetstine Journal: Genes Dev Date: 2015-05-15 Impact factor: 11.361
Authors: M Ampuja; T Rantapero; A Rodriguez-Martinez; M Palmroth; E L Alarmo; M Nykter; A Kallioniemi Journal: BMC Genomics Date: 2017-01-11 Impact factor: 3.969
Authors: Kristina M Whately; Maria A Voronkova; Abha Maskey; Jasleen Gandhi; Juergen Loskutov; Hyeran Choi; Sila Yanardag; Dongquan Chen; Sijin Wen; Naira V Margaryan; Matthew B Smolkin; Marc L Purazo; Gangqing Hu; Elena N Pugacheva Journal: Oncogene Date: 2021-07-29 Impact factor: 8.756
Authors: Camile Castilho Fontelles; Elissa Carney; Johan Clarke; Nguyen M Nguyen; Chao Yin; Lu Jin; M Idalia Cruz; Thomas Prates Ong; Leena Hilakivi-Clarke; Sonia de Assis Journal: Sci Rep Date: 2016-06-24 Impact factor: 4.379